The National Health System (SNS) has seven Car-T therapy drugs, five industrial manufacturing, such as Axicabtagén Ciloleucel (YESCARTA), Brexucabtagén Autoleucel (Tecartus), ciltacabtagén autoleucel (Carvykti), tisagenlecleucel (Kymriah) y Vicleucel (Abecma); and two non-industrial manufacturing, which are ari-0001 and ari-0002h.
Health has updated the pharmacoclinic protocols and financing criteria for patients with HIV
As Health explained, HIV people were excluded from the access protocols for these therapies due to the lack of clinical data that endorsed their safety and efficiency in this group, as a consequence of their systematic exclusion of clinical trials.
In March 2024, he joined the pharmaceutical benefit ABECMA. As an exclusion criterion, its use in patients with HIV active infection is not contemplated, Hepatitis B virus (SHB) o Hepatitis C virus (VHC), including patients with controlled infection. Last March, the pharmacoclinic protocols of Axicabtagen Ciloleucel y brexucabtagén autoleucelallowing people with HIV infection with undetectable viral load to start treatment. Also, this April, it has been included Ciltacabtagén AutoleUhant in the pharmaceutical benefit of the SNS under the same criteria.
People with HIV infection with undetectable viral load can start treatment with CAR-T
As the ministerial department has announced, These medications are now available in the medication financing search engine Bifimedwith criteria that allow access to patients with prior history of HIV infection, hepatitis B or C, provided they have undetectable viral load.
Barriers elimination
For the Ministry, this update is a fundamental step in the elimination of discriminatory barriers and the improvement of equity in the SNS, aligned with the principles of the Social pact for non -discrimination and equal treatment associated with HIV.
The measure arises from the joint work between health and entities such as HIV and AIDS State Coordinator (Cesida)that since 2021 has denounced this situation of inequality. At this point, he highlighted the collaboration of health professionals, scientific societies, patient organizations and pharmaceutical industry to technically substantiate this decision.
Related news :